Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome

Trial Profile

A Multicenter, Randomized, Double-blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Patidegib (Primary)
  • Indications Basal cell nevus syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms PATIDEGIB study
  • Sponsors PellePharm
  • Most Recent Events

    • 02 Dec 2019 According to a PellePharm media release, trial size expanded to accommodate 24 more patients than planned.
    • 02 Dec 2019 Status changed from recruiting to active, no longer recruiting, according to a PellePharm media release.
    • 01 Apr 2019 According to a PellePharm media release, the company has dosed the first patient in the trial. LEO Pharma is providing resources to PellePharm to fund this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top